Back to Search
Start Over
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
- Source :
-
BMC Cancer . 7/23/2021, Vol. 21 Issue 1, p1-9. 9p. - Publication Year :
- 2021
-
Abstract
- <bold>Background: </bold>Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC). Due to the lack of evidence to directly compare them, we conducted this network meta-analysis to indirectly compare the effectiveness and toxicity of modified FOLFIRINOX and GEM-NAB.<bold>Methods: </bold>The eligible retrospective studies on treatments related to modified FOLFIRINOX and GEM-NAB up to 4 April 2020 were searched and assessed. We used the frequentist model to analyze the survival and toxicity data between different treatments. Pooled analysis for overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and events of toxicity were analyzed in this study.<bold>Results: </bold>Twenty-two studies were involved in this network meta-analysis. The comparisons on OS and PFS showed that modified FOLFIRINOX and GEM-NAB had similar treatment efficacy (OS: 1.13; 95% CI: 0.78-1.63; PFS: HR: 1.19; 95% CI: 0.85-1.67). GEM-NAB was more effective than modified FOLFIRINOX based on the result of ORR (RR: 1.43; 95% CI: 1.04-1.96). Moreover, our analysis showed a similar toxicity profile between modified FOLFIRINOX and GEM-NAB.<bold>Conclusions: </bold>The current evidence showed that modified FOLFIRINOX and GEM-NAB were similar in survival and toxicity. Many factors should be considered for in the formulation of optimal treatment, and our meta-analysis could provide some guidance to treatment selection in the first-line setting for advanced PC. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PANCREATIC cancer
*OVERALL survival
*PROGRESSION-free survival
*SURVIVAL analysis (Biometry)
*TREATMENT effectiveness
*CANCER chemotherapy
*GEMCITABINE
*THERAPEUTIC use of antineoplastic agents
*PANCREATIC tumors
*PUBLICATION bias
*ALBUMINS
*FOLINIC acid
*RESEARCH
*META-analysis
*RESEARCH methodology
*PROGNOSIS
*ANTINEOPLASTIC agents
*DEOXYCYTIDINE
*MEDICAL cooperation
*EVALUATION research
*FLUOROURACIL
*TUMOR classification
*COMPARATIVE studies
*RESEARCH funding
*PACLITAXEL
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 21
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- BMC Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 151541176
- Full Text :
- https://doi.org/10.1186/s12885-021-08605-x